RareFinance peopleInnovationCareers PipelineCollaborationAdvance treatment SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Disclaimer

The following information about the trial with identifier NCT03943589 is taken directly from the publicly available website ClinicalTrials.gov and has not been edited.

About this trial

Status

Completed

Phase

Phase 2

Gender

All

Age

18 Years and older

Trial identifier

NCT03943589

ClinicalTrial.gov

Condition

Guillain-Barré Syndrome (GBS)

Official title

An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients

Sponsor

Hansa Biopharma

Locations

For a complete list of locations, please visit:ClinicalTrial.gov

Eligibility criteria

Inclusion Criteria

  1. Signed Informed Consent obtained before any study-related procedures.
  2. Willingness and ability to comply with the protocol.
  3. Male or female aged ≥18 years at the time of screening.
  4. GBS diagnosed according to National Institute of Neurological Disorders and Stroke (NINDS) diagnostic criteria (Asbury et al. 1990).
  5. Onset of weakness due to GBS is not more than 10 days prior to screening.
  6. Unable to walk unaided for >10 meters (grade ≥ 3 on GBS DS).
  7. IVIg treatment being considered.
  8. Women of child-bearing potential willing or able to use at least one highly effective contraceptive method from the day of treatment until at least 6 months after the dose of imlifidase if not abstinent. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
  9. Men willing to use double-barrier contraception from the day of treatment until at least 2 months after the dose of imlifidase if not abstinent.

Exclusion Criteria

  1. Previous treatment with imlifidase.
  2. Previous IVIg treatment within 28 days prior to imlifidase treatment.
  3. Subjects who are being considered for, or already on, PE.
  4. Women of child-bearing potential willing or able to use at least one highly effective contraceptive method from the screening visit until at least 180 days following imlifidase dosing.
  5. Breastfeeding or pregnancy
  6. Clinical evidence of a polyneuropathy of another cause e.g. diabetes mellitus (except mild sensory), alcoholism, vitamin deficiency, or porphyria.
  7. Known selective immunoglobulin A (IgA) deficiency.
  8. Hypersensitivity to IVIg or to any of the excipients.
  9. Immunosuppressive treatment (e.g. azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus or > 20 mg prednisolone daily) during the last month.
  10. Subject known to have a severe concurrent disease, e.g. malignancy, severe cardiovascular disease and severe chronic obstructive pulmonary disease (COPD).
  11. Any condition that in the opinion of the investigator could increase the subject's risk by participating in the study or confound the outcome of the study.
  12. Known mental incapacity or language barriers precluding adequate understanding of the Informed Consent information and the study activities.
  13. Subjects with clinical signs of ongoing infection.
  14. Subjects should not have received other investigational drugs within 5 half-lives prior to imlifidase dosing.
  15. Present or history of thrombotic thrombocytopenic purpura (TTP), or known familial history of TTP.
  16. Positive PCR test for SARS-CoV-2 virus infection.
Hansa Biopharma logo

Privacy matters

When we collect your personal information, we always inform you of your rights and make it easy for you to exercise them. Where possible, we also let you manage your preferences about how much information you choose to share with us, or our partners.

©2023 Hansa Biopharma. Hansa Biopharma, the beacon logo, and IDEFIRIX are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.